The Final Appraisal Determination for the Technology Appraisal of ceritinib for ALK positive non-small-cell lung cancer has been withdrawn and the Appraisal suspended because an error has been identified in ERG exploratory scenarios that were fundamental to decision making.
Further details will follow once they are available.